| Literature DB >> 34376056 |
Sarah R Oikemus1, Edith L Pfister2, Ellen Sapp3, Kathryn O Chase2, Lori A Kennington2, Edward Hudgens1, Rachael Miller2, Lihua Julie Zhu1, Akanksh Chaudhary1, Eric O Mick4, Miguel Sena-Esteves5, Scot A Wolfe1,6, Marian DiFiglia3, Neil Aronin2,7, Michael H Brodsky1.
Abstract
Huntington's disease (HD) is a devastating, autosomal dominant neurodegenerative disease caused by a trinucleotide repeat expansion in the huntingtin (HTT) gene. Inactivation of the mutant allele by clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 based gene editing offers a possible therapeutic approach for this disease, but permanent disruption of normal HTT function might compromise adult neuronal function. Here, we use a novel HD mouse model to examine allele-specific editing of mutant HTT (mHTT), with a BAC97 transgene expressing mHTT and a YAC18 transgene expressing normal HTT. We achieve allele-specific inactivation of HTT by targeting a protein coding sequence containing a common, heterozygous single nucleotide polymorphism (SNP). The outcome is a marked and allele-selective reduction of mHTT protein in a mouse model of HD. Expression of a single CRISPR-Cas9 nuclease in neurons generated a high frequency of mutations in the targeted HD allele that included both small insertion/deletion (InDel) mutations and viral vector insertions. Thus, allele-specific targeting of InDel and insertion mutations to heterozygous coding region SNPs provides a feasible approach to inactivate autosomal dominant mutations that cause genetic disease.Entities:
Keywords: Huntington's disease; gene editing; single nucleotide polymorphism
Mesh:
Substances:
Year: 2022 PMID: 34376056 PMCID: PMC8819514 DOI: 10.1089/hum.2020.323
Source DB: PubMed Journal: Hum Gene Ther ISSN: 1043-0342 Impact factor: 5.695